Published in TB and Outbreaks Week, January 22nd, 2002
With this increase in revenues, gross profits will continue to remain at high levels. The steady growth of BioShield's sales over the past year (reflecting 50% quarterly growth rates) and growing acceptance of its products in worldwide markets is expected by management to continue returning a high growth rate over the upcoming year.
Over the course of the year, the company adjusted expenses in line with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week